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Peri-implant inflammations represent serious diseases after dental implant treatment, which affect both the
surrounding hard and soft tissue. Due to prevalence rates up to 56%, peri-implantitis can lead to the loss of the
implant without multilateral prevention and therapy concepts. Specific continuous check-ups with evaluation and
elimination of risk factors (e.g. smoking, systemic diseases and periodontitis) are effective precautions. In addition
to aspects of osseointegration, type and structure of the implant surface are of importance. For the treatment of
peri-implant disease various conservative and surgical approaches are available. Mucositis and moderate forms of
peri-implantitis can obviously be treated effectively using conservative methods. These include the utilization of
different manual ablations, laser-supported systems as well as photodynamic therapy, which may be extended by
local or systemic antibiotics. It is possible to regain osseointegration. In cases with advanced peri-implantitis surgical
therapies are more effective than conservative approaches. Depending on the configuration of the defects, resective
surgery can be carried out for elimination of peri-implant lesions, whereas regenerative therapies may be applicable
for defect filling. The cumulative interceptive supportive therapy (CIST) protocol serves as guidance for the treatment of
the peri-implantitis. The aim of this review is to provide an overview about current data and to give advices regarding
diagnosis, prevention and treatment of peri-implant disease for practitioners.
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Dental implants have become an indispensable estab-
lished therapy in dentistry in order to replace missing
teeth in different clinical situations. Success rates of
82,9% after 16 years follow-up have been reported [1].
Under care and attention of indications, anatomical and
intra-individual limiting factors, insertion of dental im-
plants seems to represent a “safe” treatment option.
Nevertheless, in the last decades increasing evidence
raised on the presence of peri-implant inflammations
representing one of the most frequent complications af-
fecting both the surrounding soft and hard tissues which
can lead to the loss of the implant. Therefore, strategies
for prevention and treatment of peri-implant disease
should be integrated in modern rehabilitation concepts in
dentistry. The present review gives an updated overview* Correspondence: r.smeets@uke.de
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unless otherwise stated.on the pathogenesis, etiology, risk factors and prevention
of peri-implantitis, but also on actual recommendations in
treatment and therapy options.Review
Definition und pathogenesis
In analogy to gingivitis and periodontitis affecting the
periodontium of natural teeth, an inflammation and de-
struction of soft and hard tissues surrounding dental im-
plants is termed as mucositis and peri-implantitis [2-4].
Thereby, transitions are often fluent and not clinically
clearly separable [5].
Mucositis describes a bacteria-induced, reversible in-
flammatory process of the peri-implant soft tissue with
reddening, swelling and bleeding on periodontal probing
(Figure 1) [2-6]. These are typical signs, but they are
sometimes not clearly visible. Furthermore, bleeding on
probing (BOP) might be an indicator for peri-implant
disease, but sufficient evidence according to the predict-
ive value of BOP is still lacking [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Peri-implantitis with increased probing depth (12 mm).
Smeets et al. Head & Face Medicine 2014, 10:34 Page 2 of 13
http://www.head-face-med.com/content/10/1/34In contrast to mucositis, peri-implantitis is a progres-
sive and irreversible disease of implant-surrounding hard
and soft tissues and is accompanied with bone resorp-
tion, decreased osseointegration, increased pocket for-
mation and purulence [2-6]. Bleeding on probing, bone
loss and deep probing depths may have other reasons
than inflammation, e.g. too deep insertion of the implant
[8]. Moreover, type and shape oft the implant, connec-
tion type, abutment and suprastructure material and the
type of prosthetic suprastructure affect the peri-implant
soft and hard tissues [7].
Depending on the configuration of the bony defect,
Schwarz et al. distinguished between an intraosseous
class I defect and a supra-alveolar class II defect in the
crestal implant insertion area [5]. Spiekermann charac-
terized the type of bone resorption into horizontal (class
I), key-shaped (class II), funnel- and gap-like (class III a,
b) as well as horizontal-circular (class IV) forms [9].
However, it is not possible to conclude progression and
prognosis criteria from these classifications.
On a microscopic and molecular level, striking diffe-
rences between peri-implant tissue and intact peri-
odontium can be determined (Table 1). Due to the
reduced vascularization and parallel orientation of the
collagen fibres, peri-implant tissues are more susceptible
for inflammatory disease than periodontal tissues. This
phenomenon can be verified immunohistochemicallyTable 1 Comparison of peri-implant mucosa with physiologic
Peri-implant mucosa
Desmosomes and hemidesmosomes of epithelium and junctional e
Direct bone-to-implant contact An
Subepithelially more collagen fibers and less fibroblasts/vessels
Parallel collagen fibers in relation to implant surfacethrough increased formation of inflammatory infiltrate,
nitric oxide 1/3, VEGF, lymphocytes, leukocytes and Ki-
67 [10]. Besides, in analogy to periodontitis the level of
matrix-metalloproteinases (MMP), such as MMP-8, is
increased up to 971% in peri-implant lesions. The latter
can be used for disgnostic purposes [11-13].
A differentiation of peri-implantitis to other inflam-
matory periodontal processes cannot be made on the
basis of human saliva by markers such as osteocalcin,
tartrate-resistant acid phosphatase (TRAP), dickkopf-
related protein-1 (DKK-1), osteoprotegerin (OPG) and
cathepsin K (CatK) [9,14].
Etiology and epidemiology
There are several reports on the prevalence of mucositis
and peri-implantitis that differ between 5% and 63.4%.
This enormous range is mainly based on varying study
designs and population sizes with different risk profiles
and statistic profiles [5,15-18].
Zitzmann et al. quantified the incidence of the devel-
opment of peri-implantitis in patients with a history of
periodontitis almost six times higher than in patients
with no history of periodontal inflammation [3]. After
10 years, 10% to 50% of the dental implants showed
signs of peri-implantitis [19,20]. Based on the Consensus
Report of the Sixth European Workshop in Periodontol-
ogy, Lindhe & Meyle reported an incidence of mucositis
of up to 80% and of peri-implantitis between 28% and
56% [21].
However, the prevalence of peri-implant diseases, evalu-
ated recently by Mombelli et al., revealed peri-implantitis
in 20% of all implanted patients and in 10% of all inserted
implants. Although this percentage has to be interpreted
with caution because of the variability of the analyzed
studies [7], it underlines the fact that bone remodeling
processes often result in marginal bone loss during the
first weeks after abutment connection which cannot be
regarded as peri-implantitis. This led to the recommenda-
tion to take a radiograph after insertion of the suprastruc-
ture and to consider it as a basis for any future assessment
of peri-implant bone loss.
Frequently, a spectrum of pathogenic germs can be de-
tected such as Prevotella intermedia, Prevotella nigrescens,
Streptococcus constellatus, Aggregatibacter actinomycetem-
comitans, Porphyromonas gingivalis, Treponema denticola
and Tannerella forsythia [3,22]. Rams et al. revealed 71.7%al periodontium [3,5]
Physiological periodontium
pithelium (biological width) are linked with the contact surface
choring system of root cementum, alveolar bone and desmodontic fibers
Subepithelially more fibroblasts and vessels
Dentogingival, dentoperiostal, circular and transseptal fiber orientation
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of 120 patients [22]. Peri-implantitis is a poly-microbial an-
aerobic infection [23]. However, in contrast to periodontitis,
peri-implantitis lesions harbor bacteria that are not part of
the typical periodontopathic microbiota. In particular,
Staphylococcus aureus appears to play a predominant role
for the development of a peri-implantitis. This bacterium
shows an high affinity to titanium and has according to the
results of Salvi et al. a high positive (80%) and negative
(90%) predictive value [24]. As another beneficial cause,
smooth implant surfaces in comparison to rough surfaces
can accelerate the peri-implant inflammation [10,17,25].
Risk factors and prevention
Implant loss may occur as “early implant loss” up to one
year after implant insertion and “delayed implant loss”
with a time period of more than one year after implant
insertion [3]. The following factors or circumstances
have been reported as risk factors for the development
of peri-implantitis [5,6,16,26-33]:
 Smoking with additional significantly higher risk of
complications in the presence of an positive
combined IL-1 genotype polymorphism.
 History of periodontitis.
 Lack of compliance and limited oral hygiene
(including missing checkups).
 Systemic diseases (e.g. maladjusted diabetes mellitus,
cardiovascular disease, immunosuppression).
 Iatrogenic causes (e.g. “cementitis”).
 Soft tissue defects or poor-quality soft tissue at the
area of implantation (e.g. lack of keratinized gingiva).
 History of one or more failures of implants.
Studies indicate smoking as the greatest identifiable
and most often cited risk factor for peri-implant disease
followed by a history of periodontitis. Both are related to
higher prevalences of peri-implantitis [7]. The presence
of periodontitis or cigarette smoking increased the risk
for peri-implantitis up to 4.7-fold as reported by
Wallowy et al. [6]. Moreover, smoking has been shown
to be a predictor for implant failure [31]. In a recent
meta-analysis smoking increased the annual rate of bone
loss by 0.16 mm/year and represented the main systemic
risk factor [34]. The extent of osseointegration as well as
the oral hygiene around dental implants was found to be
reduced among smokers [35]. It is commonly accepted
that the outcome of almost all intraoral therapeutic pa-
rameters are negatively affected by smoking although
not in all previous studies a positive correlation between
peri-implantitis and tobacco smoking could be found
[36,37]. Evidence of predictors for implant success such
as gender or age could not be found but for the jaw of
treatment (maxillary versus mandibular implants). In astudy by Vervaeke et al. maxillary implants were at a sig-
nificantly higher risk for peri-implant bone loss com-
pared to mandibular implants [31]. Bone augmented
areas could not be determined as risk factors for implant
failure or increased peri-implant disease [38].
Across an observation period of 10 years in a group of
patients with periodontitis, the previously eliminated
bacterial strains of Aggregatibacter actinomycetemcomi-
tans and Porphyromonas gingivalis could again be de-
tected in the oral mucosa [3]. Prevotella intermedia was,
however, continuously evident. This indicates a niche
survival of bacteria after tooth extraction with recur-
rence of the same microflora after a short period of time.
In particular, attention should be paid to the remaining
teeth with periodontitis as a potential source of infec-
tion. Therefore, the type of dentition (edentulous versus
partially edentulous) may influence the colonization of
peri-implant tissues with periodontal pathogens [38].
The impact of keratinized gingiva around dental im-
plants has been controversially discussed, but most stud-
ies emphasize the importance of an adequate zone of
keratinized tissue surrounding implants [39-41]. The so
called “cementitis” may be regarded as the most import-
ant identifiable iatrogenic risk factor since its first de-
scription by Wilson et al. in 2009 [42]. The latter group
revealed that residual dental cement in a group of pa-
tients with clinical or radiographic signs of peri-implant
disease was present in 81% of the sites. After its removal,
clinical signs were absent in 74% of the affected sites.
Korsch et al. found that the removal of cement remnants
led to a decrease of the inflammatory response by almost
60% [43]. Linkevizius et al. examined the manifestation
of peri-implantitis in a group of patients with present ce-
ment remnants. In those who had a history of periodon-
titis, peri-implantitis was found in 100% of the patients,
whereas cement remnants in patients with no previous
periodontal disease ended up in 65% peri-implantitis
manifestations [30]. Another preventive arrangement re-
garding antibacterial precautions are internal connec-
tions with inward located microgap, which should be
preferred. [6].
Peri-implant probing is recommended to be carried
out carefully with a minimal probing force. However, the
so-called platform switch (abutment is located horizon-
tally between implant and crown) can complicate prob-
ing and, thus, hide the true extension of peri-implantitis
[3,5,17,26,44]. Nevertheless, studies have indicated that
platform switch might be an important protective factor
against peri-implant disease [45].
Implant loss can be differentiated on the basis of the
following additional factors [3,5,6,46-49]:
 Overloading of the implant,
 Faults in material and techniques,
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 Systemic diseases and drug therapies, which inhibit
bone modulations according to “Wolff ’s law” (bone
density and strength increase with stress - and vice
versa).
Thus, implants of more than 10 mm length in square
thread design show higher success rates than shorter
implant lengths or shapes without thread or buttress
thread [48,49]. Also rough implant surfaces of more
than 2 microns seem to feature better osseointegration
than smooth (<0.5 microns) or moderate surfaces (1–2
microns) [17].
Development of strengths in the temporomandibular
joint of more than 1300 Newton may shift the implants
in the first few months of healing up to 100 microns by
presence of sagittal forces acting from an average of 50
Newton [46]. These average reference forces even in-
crease to 87 Newton when articulation angles up to 60°
in horizontal axis.
In addition to patient training sessions for optimal oral
hygiene, preventive strategies such as professional tooth
and implant cleaning as well as individually continuous
peri-implant examinations (probing status) should be
considered in order to prevent peri-implant diseases
(Table 2) [6]. Attention has to be paid, in particular, to
the reduction of the above-mentioned risk factors such
as heavy smoking or diabetes mellitus.
As part of a holistic therapy, so-called reference pa-
rameters (“hour zero”) and clearly determined control
procedures have to be assessed with adequate docu-
mentation. Radiographs should be taken pre-, intra-
and post operatively in order to get information about
the implantation site in which peri-implant inflamma-
tion will be detectable as brightening zones indicating
increased bone resorption [6].
Prevention of peri-implant disease starts with a suf-
ficient and structured planning including individual
evaluation and minimization of risk factors (smoking,
compliance, oral hygiene, periodontal disease, systemic
diseases), establishment of optimal soft and hard tissue
conditions, the choice of the correct implant design
followed by a maximally atraumatic approach and
regular clinical examinations with a periodontal prob-
ing status.Table 2 Numbers of check-ups (cu) annually for different pati
cu = 1 cu = 2
Oral hygiene and hygienic ability of the implant well middle
Smoking status / in history
Periodontitis, mucositis (with history) / /
Other risk factors / /Therapy
The treatment of peri-implant infections comprises con-
servative (non-surgical) and surgical approaches. De-
pending on the severity of the peri-implant disease
(mucositis, moderate or severe peri-implantitis) a non-
surgical therapy alone might be sufficient or a step-wise
approach with a non-surgical therapy followed by a sur-
gical treatment may be necessary.
Therapy of mucositis
One of the main aims of peri-implant therapy is to de-
toxify the contaminated implant surface. In the presence
of peri-implant mucositis, non-surgical methods are ap-
propriate and sufficient for detoxification. These include
mechanical implant cleaning with titanium or plastic-
curettes, ultrasonics or air polishing. Moreover, photo-
dynamic therapy as well as local antiseptic medication
(chlorhexidinglukonate, hydrogen peroxide, sodium per-
carbonate, povidone-iodine) may support the antimicro-
bial therapy.
In two randomized clinical trials Heitz-Mayfield et al.
and Hallström et al. were not able to prove any benefits
in reduction of pocket depth, plaque index or purulency
when adjuvant antimicrobial therapy (chlorhexidine and
azithromycine) was used in addition to mechanical ther-
apy only [50,51]. Reductions of the bleeding index were
explained by the general improvement of oral hygiene
with reference to the potential importance of guidelines
and treatment protocols [50-52]. The establishment of
an adequate oral hygiene should, therefore, be consid-
ered as key issue of the prevention of peri-implant infec-
tions. Besides, a maintenance program with regular
evaluation of the peri-implant probing depths, support-
ive professional implant cleaning and oral hygiene train-
ing should be integral part of every post-operative care
after implant insertion [2,6].
Therapy of peri-implantitis
Most of the published strategies for peri-implantitis
therapy are mainly based on the treatments used for
teeth with periodontitis. The reason is that the way of
bacterial colonization of dental and implant surfaces fol-
low similar principles, and it is commonly accepted that
the microbial biofilm plays an analogous role in the de-
velopment of peri-implant inflammation [53]. For theent collectives
cu > 3
bad
in presence
in presence
e.g. systemic diseases, history of an non-successful implant insertion
Figure 3 Conservative therapy – detoxification using an air
polishing device with glycin powder.
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surgival) as well as surgical therapies can be applied.
Thereby, the surgical treatments can be done using
resective or regenerative approaches [54-59].
Conservative therapy
In addition to medication and manual treatment (e.g.
with curettes, ultrasonic and air polishing systems) in-
novative techniques such as laser-supported and photo-
dynamic therapy methods are recently described as
conservative therapy options.
Manual treatment
Basic manual treatment can be provided by teflon-,
carbon-, plastic- and titanium curettes (Figure 2).
Due to the fact that therapy with conventional curettes
is able to modify the implant surface and can roughen
the surface, it has been recommended that the material
of the tip should be softer than titanium [60,61]. It is
possible to reduce bleeding on probing scores by clean-
ing with piezoelectric scalers as well as with hand instru-
ments, and no differences have been found between
these methods concerning reduction of bleeding on
probing, plaque index and probing depths after at least
6 months [62,63].
As to the above-mentioned methods, the efficacy of
ultrasonic curettage seems to underly the use of air pol-
ishing systems (Figure 3) [5,62,64-68]. Persson et al. and
Renvert et al. experienced significantly lower numbers of
bacteria with partial reduction of plaque and bleeding
scores after mechanical curettage, while Schwarz et al.
reported 30%-40% less residual biofilm areas by using
ultrasonic methods [5,63,66]. Depending on the surface
topography of the implants, Louropoulou et al. recom-
mend different therapeutic methods (Table 3).
The results of air polishing systems are depending on
the used medium and are significantly better in the fol-
lowing order: hydroxylapatite/tricalcium phosphate >Figure 2 Conservative therapy – example of the use of a
carbone curette.hydroxylapatite > glycine > titanium dioxide > water and
air (control group) > phosphoric acid [64].
An abrasive air polishing medium can modify the sur-
face of implants. After air powder treatment cell attach-
ment and cell viability still showed sufficient levels, but
cell response was decreased compared with sterile sur-
faces [64,65,67]. The extent of re-osseointegration of ti-
tanium implants after air polishing therapy has been
reported between 39% and 46% with increased clinical
implant attachment and pocket depth reduction [65].
The occurrence of bleeding on probing, one of the quali-
tative parameters in the presence of a peri-implantitis,
could be significantly reduced [67].
Drug therapy
There are numerous in vitro and in vivo studies on the ap-
plication of medicaments as part of the treatment of mu-
cositis and peri-implantitis. However, due to differences in
the design of all studies, comparison of these studies is dif-
ficult. The following therapies can be distinguished:
 Antiseptic rinses in relation to different parameters.
 Application of systemic and locally delivered
antibiotics in relation to pocket depth or different
parameters.
In a review by Javed et al., summarizing nine studies,
systemic and local antibiotic applications (e.g. tetracycline,
doxycycline, amoxicillin, metronidazole, minoxicycline
hydrochloride, ciprofloxacin, sulfonamides + trimetho-
prim) led to significant reductions of pocket depths in
a period between one and six years [69]. Moura et al.
noticed the same for resorbable doxicycline releasing
nanospheres in local application over a period of
15 months [70]. Leonhardt et al. noticed an overall
Table 3 Qualitative effectiveness (x: yes/o: no) of different cleaning methods depending on implant surface [68]
Smooth surface Sandblasted and acid-etched surface (SLA) Plasma sprayed surface
Rubber cap o o o
Metalic curette, rotating titanium brush o x x
Plastic curette o o o
Ultrasonic systems with metalic tips x (polished)
Ultrasonic systems with plastic tips o x x
Air polishing x x x
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surgical debridement and the use of various antibiotics
and combinations of them (including clindamycin,
amoxicillin + metronidazole, tetracycline, ciprofloxa-
cin) [71].
Astasov-Frauenhoffer et al. were able to prove complete
growth-inhibiting effects of amoxicillin and metronidazole
on Streptococcus sanguinis, Porphyromonas gingivalis and
Fusobacterum nucleatum apart from each other, but the
combination was found to be more efficient than metro-
nidazole alone [72]. Comparing local antibiotic therapy
with photodynamic therapy, Bassetti et al. presented no
differences in reduction of pocket depths or reduction of
the number of bacteria in the periodontal pockets [73].
Grapefruit juice, known as antioxidant, had only a bac-
teriostatic effect against Streptococcus aureus [74]. But is
has to be considered that depending on the type, bacteria
demonstrate different high resistances against antibiotics
(Table 4). Submucosal biofilm specimens were cultured
from patients with peri-implantitis and after in vitro
testing for susceptibility especially the combination of
amoxicillin and metronidazole showed significant lower
resistances (6.7%) [22].
Application of chlorhexidine resulted in the reduction
of pocket depths, a higher implant adhesion and general
weakening of inflammation measured by the level of the
inflammatory markers IL-1 beta, VEGF and PGE-2 in
various studies [75-77]. Compared to minocycline
microsphere application repeated every three months
[78], the treatment with 1% chlorhexidine gel resulted
in significantly less reduced pocket depths after 12 months.
Concerning tissue engineering, Lan et al. demonstrated a
continuous release-kinetic of metronidazole for 30 daysTable 4 Antibiotic resistance of Prevotella intermedia,
Prevotella nigrescens and Streptococcus constellatus
(n = 120) [22]
Antibiotic Resistance
Clindamycin 46,7%
Amoxicillin 39,2%
Doxycycline 25%
Metronidazole 21,7%
Amoxicilin & metronidazol 6,7%using a Poly-ε-Caprolacton/Alginat-ring [79]. Hou
et al. incorporated fluorouracil into cylindrical poly-ε-
caprolactone-implants of different diameters [80].
Local or systemic antibiotics are an additional therapy
option. In combination with other conservative or surgi-
cal treatments it results in more efficient reductions of
clinical peri-implantitis symptoms [81]. Just administra-
tion of antibiotics is no treatment option.
Laser therapy
By means of a bactericide mode of action, CO2, Diode-,
Er:YAG- (erbium-doped: yttrium-aluminum-garnet)
and Er,Cr:YSGG- (erbium, chromium-doped: yttrium-
scandium-gallium-garnet) lasers are used in the treatment
of peri-implant diseases with increasing frequency. Min-
imal absorption and reverberations must be ensured with
the purpose to protect implant and tissue. Er:YAG and Er,
Cr :YAG with a wavelength of 3 microns can reduce bio-
films up to 90% but in contrast to most mechanical ther-
apies any biological compatibilities and cell stimulatory
properties can’t be re-induced [5,82,83]. Treatment with a
CO2 308 nm excimer laser, however, led mainly and effi-
ciently to satisfactory results in an anaerobic bacteria
spectrum [84].
In comparison to mechanical methods (plastic curettes),
treatments with an Er:YAG laser led to significantly better
results in terms of bleeding at peri-implantitis. However,
both methods showed no significant differences in
changes of pocket depths, clinical attachment level, plaque
index and gingival recessions, although in both groups
these parameters were improved [85].
Persson et al. examined the effectiveness of Er:YAG la-
sers compared to an air polishing system in a random-
ized clinical trial with 42 patients over 6 months [86].
Except for different reducing effects on specific bacteria
strains after one month (Er:YAG: Fusobacterium nuclea-
tum; air polishing system: Pseudomonas aeruginosa,
Staphylococcus aureus and Peptostreptococcus anaerobius)
there were no long term-reducing effects shown after
6 months. In a recent study Mailoa et al. showed that
laser therapy resulted in similar reductions of probing
depths when compared to other decontamination
methods [87]. Although there is only few data in com-
parison to manual and surgical therapy, laser therapy as
Table 5 AKUT-protocol by Lang et al. [93]
Stage Result Therapy
Pocket depth (PD) <
3 mm, no plaque or
bleeding
No therapy
A PD < 3 mm, plaque and/
or bleeding on probing
Mechanically cleaning, polishing,
oral hygienic instructions
B PD 4-5 mm, radiologically
no bone loss
Mechanically cleaning, polishing,
oral hygienic instructions plus local
antiinfective therapy (e.g. CHX)
C PD > 5 mm, radiologically
bone loss < 2 mm
Mechanically cleaning, polishing,
microbiological test, local and
systemic antiinfective therapy
D PD > 5 mm, radiologically
bone loss > 2 mm
Resective or regenerative surgery
Figure 4 Peri-implantitis with granulation tissue.
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Further studies are needed to evaluate the profit of laser
therapy in peri-implantitis treatment.
Photodynamic therapy
Photodynamic therapy generates reactive oxygen species
by multiplicity with help of a high-energy single-frequency
light (e.g. diode lasers) in combination with photosen-
sitizers (e.g. toluidine blue). In a wave length range of 580
to 1400 nm and toluidine blue-concentrations between 10
and 50 ug/ml, photodynamic therapy generates bactericide
effects against aerobic and anaerobic bacteria (such as
Aggregatibacter actinomycetemcomitans, Porphyromonas
gingivalis, Prevotella intermedia, Streptococcus mutans,
Enterococcus faecalis) [5,88,89]. The only prospective ran-
domized clinical trail by Basseti et al. covered 12 months
of follow-up. After manual debridement by titanium cu-
rettes and glycine air powder treatment half of the patients
received adjunctive photodynamic therapy and the other
half received minocycline microspheres into implant
pockets. After 12 months, the number of periopathogenic
bacteria and level of IL-1β decreased significantly in both
groups without significant differences between them [73].
In a study by Deppe et al. regarding to the effectiveness of
phototherapy on a moderate and severe peri-implantitis,
both clinical attachment and bleeding index were signifi-
cantly reduced suggesting that severe cases still resulted in
bone resorption [90].
As a recommendation, photodynamic therapy has to be
considered as an additional treatment option. Due to the
fact that it is a relatively new approach, the data is rare
and there are no long-term-studies available. Further
evaluations and prospective clinical trials are needed for
evaluation.
Surgical therapy
The surgical therapy combines the concepts of the
already mentioned non-surgical therapy with those of
resective and/or regenerative procedures. The indication
for the appropriate treatment strategy has been demon-
strated in patient studies leading to the development of
the “cumulative interceptive supportive therapy (CIST)”
concept [91-93]. In 2004 it was modified and called
AKUT-concept by Lang et al. (Table 5) [93]. The basis
of this concept is a regular recall of the implanted pa-
tient and repeated assessment of plaque, bleeding, sup-
puration, pockets and radiological evidence of bone loss.
A further commonly accepted concept by Zitzmann
et al. is referred to systematic periodontitis therapy. Du-
ring the initial phase oral hygienic conditions have to be
improved and mechanical cleaning and local antiinfective
treatments are applied, if necessary. If non-surgical treat-
ment fails, surgical intervention with open debridement
and resective or regenerative therapy is recommended [3].The concept of Schmage follows the CIST-protocol but rec-
ommends always mechanical and local disinfective treat-
ments in stage A and B. Intervention should be performed
if probing depths exceed 5 mm or are progressive as well as
under occurrence of local inflammation signs [94].
Resective therapy
In analogy to periodontitis, resective surgery has been
shown to be effective in reduction of BOP, probing depths
and clinical signs of inflammation. The basic principles
include the elimination the periimplant osseous defect
using ostectomy and osteoplasty as well as bacterial de-
contamination (Figures 4 and 5). Additionally, smooth-
ening and polishing of the supracrestal implant surface
(implantoplasty) may be applied.
Serino et al. showed that in patients with active peri-
implant disease surgical pocket elimination and bone re-
contouring in combination with plaque control before
and after surgery represents an effective treatment. Two
years after open reduction of inflammated peri-implant
soft tissue and osseous surgery 48% of the patients had
no signs of peri-implantitis and 77% of the patients had
Figure 5 Peri-implantation 1 week after resective therapy.
Figure 7 Regenerative therapie – defect fill with a xenograft
material (BioOss ®, Geistlich, Switzerland).
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and/or suppuration [56].
In a radiographic study with 3 years follow-up, Romeo
et al. showed that the marginal bone loss after resective
surgery with implantoplasty was significantly lower
than after resective therapy only [55]. The group with
additional implantoplasty also had significantly lower
probing pocket depths, probing attachment levels and
modified bleeding indices after 24 months [54].
Adjuvant implant surface decontamination with anti-
microbial substances led to an initially less anaerobic
bacteria contamination, but did not improve the clinical
outcome [75].
Resective surgical therapy for peri-implantitis is a rec-
ommendable therapy option. Ostectomy and osteoplasty
combined with implantoplasty represent an effective
therapy to reduce or even stop peri-implantitis progres-
sion. Nevertheless, due to the increased postoperative
recessions, this procedure is not suitable for every situ-
ation, especially in highly esthetic sensitive areas.Figure 6 Regenerative therapie – defect after degranulation.Regenerative approaches
Resective surgical therapy may result in re-osseointegration
in only minor superficial defects. From functional, esthetic
and long-time-survival point of views, full regeneration and
re-osseointegration is aspired. In animal models it was pos-
sible to regenerate experimentally induced defects using
various graft materials and/or resorbable membranes fol-
lowing the principles of guided bone regeneration (GBR)
(Figures 6, 7, 8, 9 and 10).
In a study by Hürzeler et al. in 1997 in dogs, there
was no significant difference between the application
of membranes only versus membranes in combinationFigure 8 Regenerative therapie – membrane application
(BioGide ®, Geistlich, Switzerland).
Figure 9 Preoperative radiograph of the peri-implant defect.
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bone or hydroxyapatite) in terms of bone regeneration.
However, the combination resulted in a greater amount of
re-osseointegration [95]. No statistical differences in re-
osseointegration could be demonstrated after treatment
with GBR using a e-PTFE reinforced membrane com-
pared to sites without this membrane [96]. The treat-
ment resulted in 60–80% bone fill of the bony defect,
but the absolute amount of re-osseointegration was
small (between 0.1 - 0.6 mm).
In contrast to debridement with surface decontamin-
ation, in most of all animal studies regenerative methods
were reported as more efficient. In general, GBR alone
and bone fill alone have been shown to be more effective
than debridement alone regarding to bone regeneration
and re-osseointegration. The results of studies using a
combination of membranes and bone graft materials
were superior to those using membranes or bone grafts
alone and tend to give the best results, However, there isFigure 10 Postoperative radiograph 12 months after
regenerative therapy.a high variability in the amount of bone fill due to differ-
ent investigation protocols and measurements [97-99]
and not in all studies there was a benefit for these treat-
ments compared to debridement alone [100-102]. The
role of submerged healing in peri-implantitis has not been
solved clearly. Although Singh et al. demonstrated in 1993
greater bone regeneration and re-osseointegration du-
ring submerged healing, Grunder et al. found no diffe-
rences between either healing method [103,104].
Additionally, there are numerous studies regarding the
treatment of peri-implantitis in humans under regenera-
tive aspects. In a retrospective study of Lagervall et al.
with 150 patients (382 implants) the most widely used
operative intervention was the periodontal flap with os-
teoplasty (47%), followed by the use of bone replacement
materials (20%). A cumulative success rate of 69% was
recorded for both procedures, which was significantly
lower in patients with risk factors such as smoking, peri-
odontal disease and poor oral hygiene [29]. Regarding to
a “regenerative” approach, autologous, allogenic and xeno-
genic bone replacement materials are often used for aug-
mentation in bone defects used with or without collagen
membrane. Allogenic and xenogenic grafts may be almost
equivalent to autogenous material [105-107]. Schwarz
et al. treated 22 patients randomly with access flap surgery
and the application of nanocrystalline hydroxyapatite in
contrast to xenogenic bone material with collagen
membrane. No significant differences were determined
between the groups, but 6 months after surgery both
treatments resulted in clinically relevant reductions in
probing depths and gains of clinical attachment level
[108]. Roos-Jansåker et al. came to similar results using
a coralline xenograft [19]. In another study bovine-
derived xenogenic material was compared with au-
togenous bone as filling material for infracrestal defects.
The xenograft provided radiologically more bone fill
and decreases in pocket depths, while bleeding on prob-
ing and suppuration were observed at both procedures
[109]. In a prospective study, 36 cases of peri-implant
bone loss were treated after local disinfection and re-
moval of granulation tissue with a 1:1 mixture of autolo-
gous bone and a xenogenic bone graft. The result was a
mean radiologically reduction of 3.5 mm from 5.1 mm
one year after treatment with an average reduction of
probing depths of 4 mm [59]. In a recent prospective case
series a combined resective and regenerative approach in-
cluding a bovine bone mineral and a collagen membrane
infracrestally and implantoplasty supracrestally showed a
significant peri-implant probing depth reduction and an
increased radiographic defect fill after 12 months of follow-
up [110]. In another study of Schwarz et al. defect cleaning
with either Er:YAG laser or plastic curettes/cotton pellets
with saline was combined with regenerative surgical proce-
dures (xenogenic bone substitute and collagen membrane).
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the chosen method of surface debridement [111].
In purpose of bone regeneration various approaches
have been described with various success rates. There is
a tendency that xenograft materials in combination with
a resorbable membranes might have advantages in terms
of re-osseointegration. Nevertheless, because of the lack
of prospective randomized clinical studies there is no
evident data concerning the long-time stability of such
“defect fillings”.Conclusion
Due to the lack of prospective randomized long-term
follow-up studies lots of approaches but no “ideal peri-
implantitis therapy” have been described. There are
many studies with different study designs in different
populations with different materials used, but the sam-
ple sizes are often too small and the follow-up is too
short. Therefore, prevention is the most important in-
strument based on appropriate treatment planning, an
atraumatic approach for implant insertion and continu-
ous check-up intervals with professional teeth and im-
plant cleaning. Above all, attention should be paid to
risk factors such as smoking and active or previous peri-
odontitis. In non-surgical therapy, combinations of
mechanical cleaning with curettes and air polishing sys-
tems are recommendable. Adjuvant antiseptic rinses and
local or systemic antibiotics are effective for short-term
bacteria eradication; laser and photodynamic therapy are
additional treatment options. However, results for long-
term benefits for these methods are missing.
Surgical therapy with resective and augmentative pro-
cedures completes the treatment options. Resective sur-
gery can be used in order to eliminate peri-implant
defects, to re-establish hygienic abilities and to reduce or
even stop peri-implantitis progression. Regenerative ap-
proaches, e.g. with xenograft materials in combination
with a resorbable membranes, are promising. The results
of bone replacement materials and autologous bone
grafts might be considered as nearly equivalent although
long-term studies are still missing and only few studies
with autologous bone material exist.
A graded systematic treatment planning according to
the CIST protocol can be recommended. The “ideal
peri-implantitis therapy”, actually, is a sum of ap-
proaches leading to an individual therapy regime con-
cerning multifactorial etiology, treatment options and
study results.Consent
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